{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:26:42Z","timestamp":1778797602277,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijgc.2025.102649","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T18:16:07Z","timestamp":1757096167000},"page":"102649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term survival analysis of a randomized phase II study of front-line chemo-immunothe-rapy with carboplatin-paclitaxel using oreg-ovomab indirect immunization in advanced ovarian cancer (QPT-ORE-002)"],"prefix":"10.1016","volume":"36","author":[{"given":"Corrado","family":"Terranova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanda","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Plotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violante","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Scollo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jada Srinivasa","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Angioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ijgc.2025.102649_bib1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/ijc.34002","article-title":"Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020","volume":"151","author":"Cabasag","year":"2022","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102649_bib2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","article-title":"Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial","volume":"21","author":"Pfisterer","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102649_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/ijgc-2022-004149","article-title":"Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions","volume":"33","author":"Caruso","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102649_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11864-014-0317-1","article-title":"Immunotherapy for ovarian cancer","volume":"16","author":"Drerup","year":"2015","journal-title":"Curr Treat Options Oncol"},{"issue":"suppl 15","key":"10.1016\/j.ijgc.2025.102649_bib5","volume":"39","author":"Secord","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102649_bib6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ygyno.2004.04.024","article-title":"CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients","volume":"94","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102649_bib7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2008.17.8400","article-title":"Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer","volume":"27","author":"Berek","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102649_bib8","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00262-020-02537-4","article-title":"Correction to: translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin\/paclitaxel plus oregovomab in ovarian cancer patients","volume":"69","author":"Battaglia","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102649_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ygyno.2019.12.024","article-title":"Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: a randomized phase II study","volume":"156","author":"Brewer","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102649_bib10","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1245\/s10434-022-12838-w","article-title":"Oregovomab plus chemo in newly diagnosed patients with advanced epithelial ovarian cancer following optimal debulking surgery (FLORA-5\/GOG-3035)","volume":"30","author":"Gregory","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102649_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CJI.0b013e31818b3dad","article-title":"The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer","volume":"32","author":"Braly","year":"2009","journal-title":"J Immunother"},{"key":"10.1016\/j.ijgc.2025.102649_bib12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102649_bib13","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.3390\/ijms22126532","article-title":"Ovarian cancer immunotherapy and personalized medicine","volume":"22","author":"Morand","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"6","key":"10.1016\/j.ijgc.2025.102649_bib14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00126839-200607060-00007","article-title":"Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13","volume":"7","year":"2006","journal-title":"Drugs R D."},{"key":"10.1016\/j.ijgc.2025.102649_bib15","article-title":"Combinatorial regimens of chemotherapeutic agents: a new perspective on raising the heat of the tumor immune microenvironment","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijgc.2025.102649_bib16","unstructured":"Oregovomab plus chemo in newly diagnosed patients with advanced epithelial ovarian cancer following optimal debulking surgery (FLORA-5). ClinicalTrials.gov. Accessed Jul 10 2025. https:\/\/clinicaltrials.gov\/search?term=NCT04498117."},{"issue":"2","key":"10.1016\/j.ijgc.2025.102649_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13543784.2021.1868436","article-title":"Oregovomab: an investigational agent for the treatment of advanced ovarian cancer","volume":"30","author":"Pietragalla","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102649_bib18","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/ijgc-00009577-200511000-00004","article-title":"A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer","volume":"15","author":"Ehlen","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2025.102649_bib19","unstructured":"Oregovomab and PLD in PARP inhibitor resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment. ClinicalTrials.gov. Accessed May 20 2025. https:\/\/clinicaltrials.gov\/study\/NCT05407584?term=oregovomab&page=2&rank=17."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25017694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25017694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:54:56Z","timestamp":1778795696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25017694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1048891X25017694"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102649","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term survival analysis of a randomized phase II study of front-line chemo-immunothe-rapy with carboplatin-paclitaxel using oreg-ovomab indirect immunization in advanced ovarian cancer (QPT-ORE-002)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102649"}}